Last updated on September 2018

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Brief description of study

This is a Phase III, double-blinded, placebo-controlled, randomized, multicenter study designed to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab + cobimetinib + vemurafenib compared with placebo + cobimetinib + vemurafenib in patients with previously untreated BRAFv600 mutation-positive metastatic or unresectable locally advanced melanoma.

Clinical Study Identifier: NCT02908672

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: CO39262 ...

Centrum Onkologii Instytut Klinika Nowotworow Ukladowych i Uogolnionych
Krakow, Poland

Reference Study ID Number: CO39262 ...

Szpital Uniwersytecki w Krakowie, Oddzia Kliniczny Kliniki Onkologii
Krakow, Poland